Extraordinary General Meeting 2017

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, are hereby given notice to attend an extraordinary shareholders’ meeting to be held at the company’s premises on Västra Trädgårdsgatan 15 in Stockholm, Sweden, on Monday, 6 February 2017 at 9:00 a.m. (CET).

Upcoming events

Silent Period

-

Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US

09:00 CET

January 21, 2022, Oncopeptides announced that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto® in the US. Investors, financial analysts and media are invited to participate in a webcast with a Q&A session on January 24, 2022, at 09:00 (CET).

Year-end report 2021

08:00 CET

Silent Period

-

Silent Period

-